Literature DB >> 12650893

[Severe Moorens ulcer: efficacy of monthly cyclophosphamide intravenous pulse treatment].

K-P Tiev1, V-M Borderie, M Briant, M Ziani, C Morvant, M Baret, A El Khattabi, T Généreau, L Laroche, J Cabane.   

Abstract

PURPOSE: Mooren's ulcer (MU) is a chronic peripheral corneal ulceration featuring conjunctival immunoglobulin deposits. It is considered as the result of a limbic immune process with hyperactivation of T and B lymphocytes. The etiology remains unknown. The response to topical steroid therapy and surgical procedures usually poor and the visual outcome can be devastating.
METHODS: Clinical follow-up of 3 patients who had rebel MU to conventional therapy, and were treated with 1g monthly intravenous cyclophosphamide.
RESULTS: First patient was a 24-years-old man who had MU in his left eye. The response to surgical procedure and intravenous steroid treatment was poor and corneal perforation occurred. The affected cornea healed after 9 months of Cy treatment. The second patient was a 50-years-old man who had MU in his left eye, which did not improved with lamellar keratoplasty and topical steroid therapy. Corneal healing was obtained after 20 months of Cy treatment. The third patient was a 70-years-old man who presented with a furrowed MU in his right eye which healed with conjunctival resection and 4 months of Cy perfusion. No adverse effects of Cy was noted as opposed to Cy given orally.
CONCLUSION: We report the effectiveness of 1g monthly intravenous cyclophosphamide (Cy) treatment in rebel MU. We suggest that immunosuppressive therapy using IV monthly Cy may be proposed in severe rebel MU.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12650893     DOI: 10.1016/s0248-8663(02)00021-8

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  3 in total

1.  Bilateral Mooren's ulcer in six patients: diagnosis, surgery and histopathology.

Authors:  Christos D Kalogeropoulos; Vassiliki D Malamou-Mitsi; Miltiadis B Aspiotis; Konstantinos G Psilas
Journal:  Int Ophthalmol       Date:  2004-01       Impact factor: 2.031

2.  Cyclophosphamide for ocular inflammatory diseases.

Authors:  Siddharth S Pujari; John H Kempen; Craig W Newcomb; Sapna Gangaputra; Ebenezer Daniel; Eric B Suhler; Jennifer E Thorne; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; C Stephen Foster
Journal:  Ophthalmology       Date:  2009-12-06       Impact factor: 12.079

3.  Amniotic membrane transplantation ineffective as additional therapy in patients with aggressive Mooren's ulcer.

Authors:  Maurice Schallenberg; Henrike Westekemper; Klaus-Peter Steuhl; Daniel Meller
Journal:  BMC Ophthalmol       Date:  2013-12-17       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.